Chief Scientific Officer

DisperSol Technologies Promotes Dave Miller to Chief Scientific Officer

Retrieved on: 
Wednesday, July 14, 2021
Biotechnology, Health, Science, Pharmaceutical, Research, Articles, Economy, Chief Scientific Officer, Civil service, Chief Scientific Officer, Occupations

DisperSol Technologies LLC announced today that it is promoting Dave A. Miller from Vice President Research & Development to Chief Scientific Officer effective immediately.

Key Points: 
  • DisperSol Technologies LLC announced today that it is promoting Dave A. Miller from Vice President Research & Development to Chief Scientific Officer effective immediately.
  • Dave is one of the worlds leading formulation scientists and, in my view, the pre-eminent expert in drug solubility and absorption enhancement, said Dr. Edward Rudnic, CEO of DisperSol Technologies.
  • It is my privilege to announce his promotion to Chief Scientific Officer.
  • As DisperSols Chief Scientific Officer, I look forward to continuing to work on and solve some of the most intractable challenges in oral small molecule development, said Dave Miller.

Freeline Announces Executive Leadership Changes

Retrieved on: 
Wednesday, June 30, 2021
Articles, Economy, Corporate governance, Chief Scientific Officer, CSO

Mr. Bircher will report to Chief Executive Officer Theresa Heggie as part of the executive leadership team.

Key Points: 
  • Mr. Bircher will report to Chief Executive Officer Theresa Heggie as part of the executive leadership team.
  • Jays deep knowledge base across manufacturing platforms, compliance, validation, quality control and regulatory matters adds tremendous value to Freeline, said Theresa Heggie, Chief Executive Officer of Freeline.
  • The Company also announced that Chief Scientific Officer (CSO), Romuald Corbau, PhD, has decided to leave Freeline to pursue other opportunities.
  • Amit Nathwani, MD, PhD, who previously served as the CSO of Freeline, will assume the CSO role on an interim basis.

Spectrum Solutions Names Dr. David J. Vigerust as Chief Scientific Officer

Retrieved on: 
Wednesday, April 14, 2021
Biotechnology, Manufacturing, Health, General Health, Medical devices, Research, Genetics, Packaging, Engineering, Science, Chemicals, Plastics, Articles, Chief Scientific Officer, Corporate governance, Economy

has been named the company\xe2\x80\x99s new Chief Scientific Officer.

Key Points: 
  • has been named the company\xe2\x80\x99s new Chief Scientific Officer.
  • Dr. Vigerust has founded, led as CEO, and previously served as chief scientific officer for a number of progressive life science and advanced biotech companies.
  • View the full release here: https://www.businesswire.com/news/home/20210414005049/en/\nSpectrum Solutions names David J. Vigerust, MS., PhD.
  • as the company\xe2\x80\x99s new Chief Scientific Officer.

NeoImmuneTech Appoints Byung Ha Lee, Ph.D., as Chief Scientific Officer

Retrieved on: 
Monday, March 1, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Articles, Chief Scientific Officer, Corporate governance, Economy, Chief Scientific Officer, NT-I7, NeoImmuneTech

NeoImmuneTech, Inc. , a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Byung Ha Lee, Ph.D., as Chief Scientific Officer (CSO) effective March 1st, 2021.

Key Points: 
  • NeoImmuneTech, Inc. , a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Byung Ha Lee, Ph.D., as Chief Scientific Officer (CSO) effective March 1st, 2021.
  • Dr. Lee brings extensive scientific experience to the leadership team, with over 15 years of diverse drug development experience.
  • In this new role, Dr. Lee will lead the effort to further demonstrate the scientific strength and maximize the scientific value of the Companys products.
  • Dr. Lee has been an integral part of our companys success thus far, and we look forward to his continued scientific leadership as our company moves into the next phase of development and growth, said Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech (NIT).

KGI Assistant Professor and Cardea Bio CSO Kiana Aran Receives National Science Foundation CAREER Award to Support Biosensor Development

Retrieved on: 
Wednesday, February 24, 2021
Science, Software, Biotechnology, Research, Hardware, Health, Technology, Semiconductor, Articles, Economy, Aran, National Science Foundation, Chief Scientific Officer

The National Science Foundation (NSF) has awarded Dr. Kiana Aran, cofounder and Chief Scientific Officer of Cardea Bio Inc., with the Faculty Early Career Development (CAREER) award.

Key Points: 
  • The National Science Foundation (NSF) has awarded Dr. Kiana Aran, cofounder and Chief Scientific Officer of Cardea Bio Inc., with the Faculty Early Career Development (CAREER) award.
  • View the full release here: https://www.businesswire.com/news/home/20210224005368/en/
    Dr. Kiana Aran, cofounder and Chief Science Officer of Cardea Bio.
  • In addition to her CSO role at Cardea Bio, Dr. Aran is assistant professor of medical diagnostics and therapeutics at KGI.
  • For more information about Cardea Bio Inc. visit www.cardeabio.com
    This material is based upon work supported by the National Science Foundation under Grant No.

Co-Diagnostics, Inc. Announces New Chief Financial Officer

Retrieved on: 
Tuesday, February 23, 2021
Articles, Economy, Business, Accounting, Financial accounting, Chief Scientific Officer

Dr. Jesse Montgomery, PhD has also been elevated to the role of Chief Scientific Officer ("CSO").

Key Points: 
  • Dr. Jesse Montgomery, PhD has also been elevated to the role of Chief Scientific Officer ("CSO").
  • Following significant growth in the past year and in anticipation of additional growth in the future, the Company has elected to add additional resources to its financial department.
  • Mr. Brown's previous experience includes CFO, Vice President of Accounting & Investor Relations, and Director of Finance roles for public and private companies.
  • Dr. Montgomery has been the Company's Senior Vice President of Biochemistry, following a career that has included research and bioinformatics scientist positions.

Kemp Proteins Elevates Carter Mitchell to Chief Scientific Officer

Retrieved on: 
Tuesday, February 2, 2021
Articles, Medicine, Biotechnology, Astra, Chris Kemp, NASA people, Chief Scientific Officer, Monoclonal antibody

FREDERICK, Md., Feb. 2, 2021 /PRNewswire-PRWeb/ --Kemp Proteins, a leading provider of gene-to-protein and monoclonal antibody development services, announced today that the company has appointed Carter Michell, Ph.D. as its new Chief Scientific Officer (CSO).

Key Points: 
  • FREDERICK, Md., Feb. 2, 2021 /PRNewswire-PRWeb/ --Kemp Proteins, a leading provider of gene-to-protein and monoclonal antibody development services, announced today that the company has appointed Carter Michell, Ph.D. as its new Chief Scientific Officer (CSO).
  • Carter will lead the scientific and technology development of Kemp Proteins as the company continues its impressive growth following its purchase by Six02 Bioservices in January 2019.
  • Prior to joining Kemp Proteins as Chief Technology Officer in mid-2020, Carter served as the Chief Technology Officer and Director of Structural Biology at a biotech start-up.
  • Carter will take over the role of CSO from the founder of Kempbio (now Kemp Proteins) Chris Kemp, who will take up a long-term advisory role as Scientist Emeritus for Kemp Proteins.

Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer

Retrieved on: 
Tuesday, January 19, 2021
Biology, Punctuated equilibrium, Race and intelligence controversy, Stephen Jay Gould, Gould, Chief Scientific Officer, Branches of biology, Skepticism

Dr. Moxham will join the executive leadership team and report to Robert Gould, Ph.D., Fulcrums president and chief executive officer.

Key Points: 
  • Dr. Moxham will join the executive leadership team and report to Robert Gould, Ph.D., Fulcrums president and chief executive officer.
  • Owen Wallace, Ph.D., will step down from his role as chief scientific officer, effective February 5, 2021 to pursue another opportunity.
  • Dr. Wallace has been appointed to Fulcrums Scientific Advisory Board and in that role will continue to provide counsel to Fulcrum on the companys research and development programs.
  • Chriss appointment to chief scientific officer reflects his strong scientific acumen and deep expertise in drug discovery, continued Dr. Gould.

Virometix Broadens Senior Leadership Team with Three Key Appointments

Retrieved on: 
Thursday, January 7, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious diseases, Clinical trials, Articles, Nicholas Stergiou, Chief Scientific Officer, Lilli, Economy

Virometix filled a vacancy in its management team with the appointment of Dr. Lilli Stergiou to the position of Chief Scientific Officer (CSO).

Key Points: 
  • Virometix filled a vacancy in its management team with the appointment of Dr. Lilli Stergiou to the position of Chief Scientific Officer (CSO).
  • Lilli has 20 years of research and development experience in multiple fields including all areas of interest to Virometix vaccines, infectious diseases, and oncology.
  • Anna Sumeray, CEO of Virometix, said: Lillis strong scientific background and her industry experience add critically important competencies to the leadership of our research programs at Virometix.
  • Harry Welten, Chairman of the Virometix Board of Directors, said: We are very pleased to welcome the three new members of our senior leadership team and look forward to their contributions to our success.

Cogstate Expands Executive Team with Key Scientific Appointments

Retrieved on: 
Thursday, October 1, 2020
Articles, Clinical research, Design, Innovation, Product management, Clinical trial, Chief Scientific Officer

These appointments represent an expansion of the executive leadership team with strengthened scientific capacity as the company continues to meet the growing demand for transformative innovations in clinical trials and healthcare.

Key Points: 
  • These appointments represent an expansion of the executive leadership team with strengthened scientific capacity as the company continues to meet the growing demand for transformative innovations in clinical trials and healthcare.
  • As Chief Science Officer, Dr. Edgar will continue to advise Cogstate customers on clinical endpoint strategy and will set the strategic vision for Cogstates global scientific services.
  • He will continue to oversee Cogstate relationships supporting innovation and development with partners from pharmaceutical and biotechnology companies and with key industry and academic groups central to the scientific advancements of Cogstate technologies.
  • Adding scientific strength to the Cogstate leadership team will further position us for this current phase of growth as we continue to see increasing demand for strong, stable delivery supported by rapid, robust innovation, said Brad OConnor, Cogstate CEO.